Large animal trial for Chondroitinase is underway

I usually check into the clinicaltrial.gov website every couple of weeks to review any new human clinical trials for spinal cord injury. However, before some treatments can safely be tested in human clinical trials, they must undergo large animal studiesdog. A special thank you goes to Dr. Nick Jeffery for this particular clinical trial taking place at Iowa State University. LINK HERE for the clinical trial information.

See the Facebook page started last week HERE: for additional photo’s and posts about the trial. Give Dr. Jeffery a “Like” while you’re there!

During the last decade, the bacterial enzyme chondroitinase has emerged as a promising intervention to treat spinal cord injury; numerous studies have demonstrated its effect on reduced scarring, preserved nerve function in the injury zone and better recovery of normal movements. However, the therapy needs further pre-clinical data gathered in models with greater clinical relevance. This new project, led by Dr Nicholas Jeffrey and Dr Ravi Bellamkonda at Iowa State University, will test the treatment in pet dogs who have sustained severe and chronic accidental spinal cord injury.

If the 3 year project demonstrates efficacy, it would provide a green light for human clinical trials with ISRT in the UK, thus accelerating the translation of the intervention from laboratory to clinic. Dr. Mark Bacon, Research Director of ISRT gave an update presentation at the annual Working 2 Walk 2013. The video library can be accessed HERE and is provided by Unite 2 Fight Paralysis.

This entry was posted in Chronic Spinal Cord Injury Research, Spinal Research and tagged , , . Bookmark the permalink.